Who is sponsoring NCT06060080?

NCT06060080 is sponsored by Yao Liu.

What drugs are being tested in NCT06060080?

Interventions in NCT06060080: pegylated recombinant human granulocyte-colony stimulating factor.

What condition does NCT06060080 study?

NCT06060080 studies Lymphoma, Multiple Myeloma.

Is NCT06060080 still recruiting?

NCT06060080 is currently status unknown. Last updated 29 September 2023.

Last reviewed 2023-09-29 · How we verify

NCT06060080

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma

Status unknown NA Last updated 29 September 2023

What this trial tests

NA trial testing pegylated recombinant human granulocyte-colony stimulating factor in Lymphoma in 7 participants. Status unknown.

Timeline

22 April 2022

Primary endpoint
31 December 2023

30 April 2024

Quick facts

Lead sponsor	Yao Liu
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	22 April 2022
Primary completion	31 December 2023
Estimated completion	30 April 2024
Sites	1 location across China

Drugs / interventions tested

pegylated recombinant human granulocyte-colony stimulating factor

Conditions studied

Lymphoma — all drugs for Lymphoma →
Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Yao Liu

Who can join

Adults 18 to 65, any sex, with Lymphoma or Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effectiveness and safety of PEG-rhG-CSF injection for the reconstruction of neutrophil cells after autologous hematopoietic stem cell transplantation in lymphoma/multiple myeloma patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of pegylated recombinant human granulocyte-colony stimulating factor

Trials testing the same drug.

NCT04547829 — Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy · Phase 2 · unknown

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06060080 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yao Liu
Last refreshed: 29 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06060080.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing